Kidney drug tested in diabetic vs non-diabetic patients – results may guide future care
NCT ID NCT07302464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a class of diabetes drugs called SGLT2 inhibitors changes kidney function in people with chronic kidney disease (CKD). Researchers compared 60 patients with and without diabetes to see if the drug affects their estimated glomerular filtration rate (eGFR) differently. The goal was to understand whether these drugs benefit both groups, not just those with diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
60 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This case-control study was done on 60 adult chronic kidney disease (CKD) individuals with stage 3 and 4 (eGFR\>\_20ml/min/1.73 m2) according to KIDGO classification at Ain Shams University Hospitals, Cairo, Egypt.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years. * Both sexes. * Chronic kidney disease (CKD) participants with stages 3 and 4. Exclusion Criteria: * Patients with type 1 diabetes mellitus (DM). * Patients with decompensated Chronic liver disease. * Patients with uncontrolled hypertension. * Patients with blood pressure (BP) \> 110/70. * Patients already on the same medication (Sodium Glucose Co-Transporter 2 Inhibitors). * Patients with a history of recurrent or recent urinary tract infection (UTI). * Patients with glycated hemoglobin (HbA1c) ≤10. * Adult polycystic kidney disease. * All patients on immunosuppressive medications.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ain Shams University
Cairo, 11591, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a breathing workout and walks help dialysis patients with irregular heartbeats?
- New pill takes aim at blood sugar in diabetes
- Home c-peptide tests could reveal hidden insulin production in diabetes
- Brain scans may predict who is most at risk for dangerous low blood sugar
- Diabetes devices put to the test: can home monitors match lab accuracy?
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?